BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19439429)

  • 1. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study.
    Hellgren K; Iliadou A; Rosenquist R; Feltelius N; Backlin C; Enblad G; Askling J; Baecklund E
    Ann Rheum Dis; 2010 Apr; 69(4):654-9. PubMed ID: 19439429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.
    Baecklund E; Iliadou A; Askling J; Ekbom A; Backlin C; Granath F; Catrina AI; Rosenquist R; Feltelius N; Sundström C; Klareskog L
    Arthritis Rheum; 2006 Mar; 54(3):692-701. PubMed ID: 16508929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
    Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
    Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
    Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis.
    Askling J; Klareskog L; Hjalgrim H; Baecklund E; Björkholm M; Ekbom A
    Ann Rheum Dis; 2005 Dec; 64(12):1765-8. PubMed ID: 15843445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
    Geborek P; Bladström A; Turesson C; Gulfe A; Petersson IF; Saxne T; Olsson H; Jacobsson LT
    Ann Rheum Dis; 2005 May; 64(5):699-703. PubMed ID: 15695534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.
    Hellgren K; Smedby KE; Feltelius N; Baecklund E; Askling J
    Arthritis Rheum; 2010 May; 62(5):1252-8. PubMed ID: 20155827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.
    Baecklund E; Sundström C; Ekbom A; Catrina AI; Biberfeld P; Feltelius N; Klareskog L
    Arthritis Rheum; 2003 Jun; 48(6):1543-50. PubMed ID: 12794821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation.
    Wolfe F; Michaud K
    Arthritis Rheum; 2007 May; 56(5):1433-9. PubMed ID: 17469100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
    Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
    Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
    Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
    Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.
    Sihvonen S; Korpela M; Mustonen J; Huhtala H; Karstila K; Pasternack A
    J Rheumatol; 2006 Sep; 33(9):1740-6. PubMed ID: 16881099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis.
    Wolfe F; Michaud K
    Arthritis Rheum; 2008 Sep; 58(9):2612-21. PubMed ID: 18759273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.
    Ekström K; Hjalgrim H; Brandt L; Baecklund E; Klareskog L; Ekbom A; Askling J
    Arthritis Rheum; 2003 Apr; 48(4):963-70. PubMed ID: 12687538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of hospitalized infection in patients with rheumatoid arthritis.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    J Rheumatol; 2008 Mar; 35(3):387-93. PubMed ID: 18260176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series.
    Dawson TM; Starkebaum G; Wood BL; Willkens RF; Gown AM
    J Rheumatol; 2001 Jan; 28(1):47-53. PubMed ID: 11196542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype.
    Smedby KE; Hjalgrim H; Askling J; Chang ET; Gregersen H; Porwit-MacDonald A; Sundström C; Akerman M; Melbye M; Glimelius B; Adami HO
    J Natl Cancer Inst; 2006 Jan; 98(1):51-60. PubMed ID: 16391371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.